Clinical Trial Update: Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase II study of rindopepimut (CDX-110) in glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Malignant Glioma

Drugs mentioned

• Rindopepimut (rindopepimut)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Malignant Glioma | Phase 2 | Status: COMPLETED